MX2022005033A - Terapia combinada antitumoral que comprende un anticuerpo anti grupo de diferenciación 19 (cd19) y linfocitos t gamma delta. - Google Patents

Terapia combinada antitumoral que comprende un anticuerpo anti grupo de diferenciación 19 (cd19) y linfocitos t gamma delta.

Info

Publication number
MX2022005033A
MX2022005033A MX2022005033A MX2022005033A MX2022005033A MX 2022005033 A MX2022005033 A MX 2022005033A MX 2022005033 A MX2022005033 A MX 2022005033A MX 2022005033 A MX2022005033 A MX 2022005033A MX 2022005033 A MX2022005033 A MX 2022005033A
Authority
MX
Mexico
Prior art keywords
lymphocytes
antibody
differentiation
combined
group
Prior art date
Application number
MX2022005033A
Other languages
English (en)
Spanish (es)
Inventor
Rainer Boxhammer
Jan Endell
Dominik Pretscher
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of MX2022005033A publication Critical patent/MX2022005033A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2022005033A 2019-10-31 2020-10-30 Terapia combinada antitumoral que comprende un anticuerpo anti grupo de diferenciación 19 (cd19) y linfocitos t gamma delta. MX2022005033A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19206479 2019-10-31
PCT/EP2020/080494 WO2021084063A1 (en) 2019-10-31 2020-10-30 Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells

Publications (1)

Publication Number Publication Date
MX2022005033A true MX2022005033A (es) 2022-09-09

Family

ID=68424789

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005033A MX2022005033A (es) 2019-10-31 2020-10-30 Terapia combinada antitumoral que comprende un anticuerpo anti grupo de diferenciación 19 (cd19) y linfocitos t gamma delta.

Country Status (23)

Country Link
US (1) US20210130461A1 (https=)
EP (2) EP4706673A2 (https=)
JP (2) JP7688025B2 (https=)
KR (1) KR20220116154A (https=)
CN (1) CN115151565A (https=)
AU (1) AU2020372646A1 (https=)
DK (1) DK4051710T3 (https=)
ES (1) ES3062643T3 (https=)
FI (1) FI4051710T3 (https=)
HR (1) HRP20251630T1 (https=)
IL (1) IL292213A (https=)
LT (1) LT4051710T (https=)
MA (1) MA69251B1 (https=)
MD (1) MD4051710T2 (https=)
MX (1) MX2022005033A (https=)
PH (1) PH12022551009A1 (https=)
PL (1) PL4051710T3 (https=)
PT (1) PT4051710T (https=)
RS (1) RS67602B1 (https=)
SI (1) SI4051710T1 (https=)
SM (1) SMT202600082T1 (https=)
TW (1) TWI883067B (https=)
WO (1) WO2021084063A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2767063C2 (ru) 2015-08-21 2022-03-16 МорфоСис АГ Комбинации и их использование
US12358983B2 (en) 2016-10-28 2025-07-15 Incyte Corporation Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
KR102617497B1 (ko) 2022-09-15 2023-12-27 주식회사 엘지에너지솔루션 음극용 자성 정렬 장치 및 이를 이용한 음극의 제조방법

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
CA2534639C (en) 2003-07-31 2013-07-30 Immunomedics, Inc. Anti-cd19 antibodies
CA2611814A1 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
ES2365046T3 (es) 2005-12-30 2011-09-21 Merck Patent Gmbh Anticuerpos anti-cd19 con inmunogenicidad reducida.
PL2383297T3 (pl) 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
RU2495882C2 (ru) 2006-09-08 2013-10-20 Медиммун, Ллк. Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания
EP2176298B1 (en) 2007-05-30 2017-11-15 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
DK2211904T3 (en) 2007-10-19 2016-10-24 Seattle Genetics Inc Cd19-binding agents and uses thereof
CN102421800A (zh) 2009-02-23 2012-04-18 格兰马克药品股份有限公司 结合cd19的人源化抗体及其用途
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
US8940707B2 (en) 2010-10-28 2015-01-27 Viropharma Incorporated Maribavir isomers, compositions, methods of making and methods of using
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
PT2710123T (pt) 2011-05-19 2017-10-13 Inst De Medicina Molecular Linha celular de linfócitos compreendendo células t gama-delta, método de composição e produção resultante dos mesmos
AU2015277516A1 (en) * 2014-06-16 2016-12-22 Xencor, Inc. Treatment for chronic lymphocytic leukemia (CLL)
IL297773B2 (en) 2014-11-17 2024-07-01 Adicet Bio Inc Engineered gamma delta t-cells
LT3302550T (lt) * 2015-05-26 2019-11-11 Morphosys Ag Anti-cd19 antikūno ir brutono tirozino kinazės inhibitoriaus derinys ir jo naudojimas
AU2016274633B2 (en) 2015-06-09 2022-04-21 Gammadelta Therapeutics Ltd Methods for the production of TCR gamma delta+ T cells
WO2017072367A1 (en) 2015-10-30 2017-05-04 Cancer Research Technology Limited EXPANSION OF NON-HAEMATOPOIETIC TISSUE-RESIDENT γδ T CELLS AND USES OF THESE CELLS
US11299708B2 (en) 2016-05-12 2022-04-12 Adicet Bio, Inc. Methods for selective expansion of γδ T-cell populations and compositions thereof
WO2018002031A1 (en) 2016-06-27 2018-01-04 Morphosys Ag Anti-cd19 antibody formulations
WO2018081648A2 (en) * 2016-10-29 2018-05-03 Genentech, Inc. Anti-mic antibidies and methods of use
GB201707048D0 (en) 2017-05-03 2017-06-14 King S College London Expansion of gamma delta cells, compositions, and methods of use thereof
TWI687227B (zh) * 2017-10-03 2020-03-11 生倍科技股份有限公司 用於t細胞免疫療法之組合及其用途

Also Published As

Publication number Publication date
RS67602B1 (sr) 2026-01-30
SI4051710T1 (sl) 2026-01-30
EP4051710B1 (en) 2025-11-26
JP7688025B2 (ja) 2025-06-03
LT4051710T (lt) 2026-03-10
MA69251B1 (fr) 2025-12-31
DK4051710T3 (da) 2025-12-15
US20210130461A1 (en) 2021-05-06
PL4051710T3 (pl) 2026-04-20
FI4051710T3 (fi) 2026-01-12
EP4051710A1 (en) 2022-09-07
IL292213A (en) 2022-06-01
TWI883067B (zh) 2025-05-11
WO2021084063A1 (en) 2021-05-06
CA3158984A1 (en) 2021-05-06
TW202131949A (zh) 2021-09-01
AU2020372646A1 (en) 2022-05-12
PT4051710T (pt) 2026-02-09
EP4706673A2 (en) 2026-03-11
KR20220116154A (ko) 2022-08-22
PH12022551009A1 (en) 2023-03-20
HRP20251630T1 (hr) 2026-02-13
JP2022554324A (ja) 2022-12-28
MD4051710T2 (ro) 2026-04-30
JP2025134705A (ja) 2025-09-17
TW202547555A (zh) 2025-12-16
CN115151565A (zh) 2022-10-04
SMT202600082T1 (it) 2026-03-09
ES3062643T3 (en) 2026-04-13

Similar Documents

Publication Publication Date Title
MX2022005033A (es) Terapia combinada antitumoral que comprende un anticuerpo anti grupo de diferenciación 19 (cd19) y linfocitos t gamma delta.
MX2019012032A (es) Tratamiento de tumores positivos a gen 3 de activacion de linfocitos (lag-3).
PH12021550553A1 (en) Pharmaceutical combinations for treating tumor comprising anti-cd19 antibody and natural killer cell
CL2018000853A1 (es) Terapia de combinación de inhibidores de bromodominios y bloqueo de puntos de control inmunitarios para tratar el cáncer.
EP4140502A4 (en) ONCOLYTIC VIRUS IN COMBINATION WITH AN IMMUNE CHECKPOINT INHIBITOR FOR THE TREATMENT OF TUMORS
PH12021551282A1 (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
MX2017000627A (es) Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
EP4286009A3 (en) Oncolytic vaccinia virus and checkpoint inhibitor combination therapy
NI202100064A (es) Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp
PH12018502652A1 (en) Combination therapies
BR112021012056A2 (pt) Inibidor da expressão gênica do hbv, agente que reduz a carga antigênica de hbv, composições para uso no tratamento de uma infecção crônica por hbv, usos de um inibidor da expressão gênica do hbv e de um agente que reduz a carga antigênica de hbv, métodos de tratamento da infecção crônica por hbv e kit
MX2019003703A (es) Método seguro y eficaz para tratar la psoriasis con el anticuerpo específico anti-il23.
MX390955B (es) Uso de un anticuerpo anti-pd-1 en combinación con un anticuerpo anti-cd30 para el tratamiento de linfoma.
EP3888648A4 (en) TREATMENT OF CANCER BY COMBINATION OF IMMUNE CHECKPOINT INHIBITOR AND FOLFIRINOX THERAPY
BR112018013063A2 (pt) combinação terapêutica inibidora de bromodomínio e proteína extra-terminal
MX387658B (es) Métodos para tratar y/o prevenir queratosis actínica.
ZA202102020B (en) Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy
CL2021000531A1 (es) Métodos de uso de un compuesto de fenoxipropilamina para tratar el dolor.
CO2021007006A2 (es) Moduladores de la expresión de irf5
WO2020005869A3 (en) Compositions and methods for the treatment of cancer characterized with pcsk9 expression
DOP2021000215A (es) Tratamiento de la cefalea usando anticuerpo anti-cgrp
ES2055314T3 (es) Tratamiento de disfuncion leucocitaria con gm-csf.
AR105621A1 (es) Anticuerpos contra cfs-1r humano para su uso en la inducción de linfocitosis en linfomas o leucemias
CL2020001429A1 (es) Tratamiento del vsr con producto combinado.
CL2019003254A1 (es) Formulación basada en vitamina e o un éster de la misma para tratar biopelículas bacterianas y fúngicas.